ABSTRACT: High-throughput screening (HTS) assays that measure the in vitro toxicity of environmental compounds have been widely applied as an alternative to in vivo animal tests of chemical toxicity. Current HTS studies provide the community with rich toxicology information that has the potential to be integrated into toxicity research. The available in vitro toxicity data is updated daily in structured formats (e.g., deposited into PubChem and other data-sharing web portals) or in an unstructured way (papers, laboratory reports, toxicity Web site updates, etc.). The information derived from the current toxicity data is so large and complex that it becomes difficult to process using available database management tools or traditional data processing applications. For this reason, it is necessary to develop a big data approach when conducting modern chemical toxicity research. In vitro data for a compound, obtained from meaningful bioassays, can be viewed as a response profile that gives detailed information about the compound's ability to affect relevant biological proteins/receptors. This information is critical for the evaluation of complex bioactivities (e.g., animal toxicities) and grows rapidly as big data in toxicology communities. This review focuses mainly on the existing structured in vitro data (e.g., PubChem data sets) as response profiles for compounds of environmental interest (e.g., potential human/animal toxicants). Potential modeling and mining tools to use the current big data pool in chemical toxicity research are also described.
■ INTRODUCTION
With the great progress of combinatorial chemistry since the 1990s, large chemical libraries became the major source of modern drug discovery procedures. 1,2 Over the past 10 years, this effort also stimulated the development of high-throughput screening (HTS) techniques. 3, 4 Traditional toxicity testing protocols using animal models are expensive and timeconsuming. Because of the urgent need to use alternative methods in toxicity studies, the U.S. National Research Council (NRC) outlined a new vision and strategies for the increased use of in vitro technologies for chemical risk assessment. 5 With its low cost and short testing time, HTS has been viewed as the potential alternative to animal models. In contrast with virtual screening techniques (e.g., QSAR or docking), HTS does not require prior knowledge about potential hits or 3D structures of involved molecular targets.
HTS is a process that screens thousands to millions of compounds using a rapid and standardized protocol. Current HTS techniques are usually combined with robotic methods. Parallel data processing and biological assay miniaturization have become more and more popular in toxicology studies, as they greatly reduce the cost of experimental testing. 3, 6 It is understandable that some popular compounds, especially those of toxicity interest (e.g., known human toxicants), have been tested multiple times and in many different bioassays. For this reason, the assay response data from multiple resources and/or multiple testing protocols could be viewed as the response profile of the compounds being tested. Figure 1 shows the current data construction of compounds in toxicity testing.
Compared to the limited amount of historical animal toxicity data, the chemical−response data space obtained from HTS is much more complex and keeps growing daily.
The term big data describes a collection of data sets that are so large and complex that they are too difficult to process by traditional data analysis tools. Originally, the big data focus was on advanced data storage and handling techniques, such as cloud-based computing or high-speed heterogeneous computational environments.
7 Currently, the problem of big data is gaining increasing recognition in clinical studies and other research areas driven by biological data. 8, 9 Clearly, the progress of HTS and relevant data sharing projects has moved modern chemical toxicity research into the big data era. The need of novel techniques, including data mining/generation, curation, storage, and management, brings new challenges and opportunities to the current toxicology community.
■ HIGH-THROUGHPUT SCREENING IN CHEMICAL TOXICOLOGY There were several important movements by regulatory agencies for the development of HTS assays that are potential alternatives to animal testing. The NIH Roadmap for medical research was launched in 2004. 10 Fueled by this initiative, several molecular library screening centers were funded by the NIH Molecular Libraries Common Fund Program. The National Institutes of Health (NIH) Chemical Genomics Center (NCGC), which is now part of the National Center for Advancing Translational Sciences (NCATS), was one of them. In 2005, the National Toxicology Program (NTP) and NCGC started a collaboration to (1) develop a chemical library suitable for quantitative HTS (qHTS), (2) develop HTS assays potentially informative for in vivo toxicity effects, and (3) experimentally test the chemical library by these qHTS assays. 4 This was one of the early efforts to systemically use the HTS technique within toxicology studies. During the same period, there were many other HTS projects that were performed by other research groups.
11−15 Although these studies were not specifically designed for chemical toxicity, but for drug discovery and other areas, these HTS efforts also generated numerous bioassay data for large chemical libraries. For the early days of HTS development, several reviews are available.
3,16−20
In 2006, the U.S. Environmental Protection Agency (EPA) initiated a research program named toxicity forecaster (ToxCast). The goal of this program was to develop methods for utilizing in vitro toxicity tests and various toxicogenomics technologies to quickly evaluate the toxic potential of chemicals and to prioritize candidates for future animal testing. 16 Phase I of ToxCast employed a chemical library of 300 unique compounds, most of which were chemicals for agricultural use, such as pesticides, and had relevant animal toxicity testing results available. 21 Around 500 cell-free or cell-based assays were used to screen this chemical library. From these, over 600 in vitro end points were measured for each chemical, generating over 200 000 concentration−response data points. In ToxCast phase II, another 767 compounds, including some failed pharmaceuticals, were screened using around 700 HTS assays.
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In 2008, another big collaborative program, called Toxicity Testing in the 21st century (Tox21), was launched by NTP, NCGC, and EPA, 23−25 joined later by the U.S. Food and Drug Administration (FDA). The Tox21 collaboration brought together its partners' expertise in the areas of experimental toxicology, in vitro assays, and informatics. 25 The target chemical library of Tox21 screening contains over 8000 unique compounds, including commercial compounds, pesticides, and marketed pharmaceuticals. 22 Screening of this extensive ■ CURRENT TOXICITY DATA SHARING PROJECTS 26 As a result, several data sharing projects, in parallel to the generation of HTS toxicity data, were also initiated during the past 10 years. For example, PubChem is a public repository for chemical structures and their biological properties. 27, 28 Most of the HTS data (e.g., those generated from the above toxicology programs) were shared through PubChem. Figure 2 shows the yearly increase of PubChem compounds. 29−34 Over the past 5 years, the number of PubChem compounds increased from 19 million in September 2008 29 to 48 million in September 2013. 33 During the same period, the number of bioassays that were deposited into PubChem increased from 1197 in September 2008 29 to over 700 000, resulting in over five terabytes of data, in September 2013. 33 The Chemical Effects in Biological Systems (CEBS) database developed by the National Institute of Environmental Health Sciences (NIEHS) is now the public repository for all NTP conventional toxicology and carcinogenicity data as well as NCGC HTS data. 35, 36 Along with the Comparative Toxicogenomics Database (CTD) at Mount Desert Island Biological Laboratory, CEBS aims to promote comparative studies of genes and proteins across species. 37−40 All of these data together can be viewed as the current toxicity big data pool, which contains over 70 million compounds, over 1 million bioassays, and around 50 billion data points. The information within this pool is being updated daily and increases rapidly (e.g., the progress of PubChem, as shown in Figure 2 ).
■ CHARACTERIZING TOXICANTS BY MULTIPLE BIOASSAY DATA
The direct consequence of the HTS testing efforts over the past 10 years is the massive amount of available biological data for organic compounds, especially those of environmental interest. A significant number of those compounds have been tested multiple times. For example, Table 2 shows 20 toxicants obtained from the Integrated Risk Information System (IRIS) database. 41 On the basis of the search result on PubChem, 42 these toxicants were reported to be tested in hundreds of PubChem bioassays. For example, chlordecone (CAS 143-50-0), an insecticide banned from the market, showed active responses in 328 bioassays (Table 2 ). Other toxicants have similarly rich response information in PubChem (Table 2) . Around 47 million compounds, over 700 000 bioassays, over 13 billion data points Toxicity, pharmaceutical, genomics, and literature data ChEMBL 87 Over 600 000 compounds, 3.3 million bioassay readout data Literature data ACToR 88, 89 The toxicity results from 100 various data resources Both in vitro and in vivo toxicity data ToxNET 90 Over 50 000 environmental compounds from 16 different resources Both in vitro and in vivo toxicity data SEURAT 91 Over 5500 cosmetic-type compounds in the current COSMOS database web portal Animal toxicity data CTD 37−40 Over 13 000 compounds, over 32 000 genes, over 6000 diseases Compound, gene, and disease relationships CEBS 35 About 10 000 toxicity bioassays from various sources Gene expression data DrugMatrix Although there are notable cases when individual in vitro assays are predictive of in vivo outcomes (e.g., assays for skin sensitization 43 and endocrine disruption 44 ), for many complex toxicity end points, single-assay data is not sufficient. The multiple bioassay data of a single compound can be viewed as its biological profile, reflecting its interactions. Profiling compounds, especially the toxicants, to study their toxicity potential is the most straightforward way to use the available bioassay data. ToxCast phase I screened over 300 unique compounds, mostly food pesticides, in 467 bioassays. The resulting data was used to profile screened compounds for their potential to induce carcinogenicity, 45 developmental toxicity, 46, 47 reproductive toxicity, 48 and endocrine disruption. 44, 49 In these studies, good correlations could be found between some bioassays and animal toxicity. For example, a model was developed by using peroxisome proliferator-activated receptor signaling assays to predict rodent carcinogenicity of 33 compounds. 45 However, although ToxCast is the most comprehensive and biggest toxicity screening project so far, using all of the available ToxCast assay data to develop a global predictive model for chemical toxicants is still questionable. 50 Besides the bioassay data generated by the ToxCast program, the Tox21 compounds have been tested in other screening projects (e.g., NCI60). 51 In the current big data era, the bioassay response profile can be very large for some compounds (e.g., those well-known toxicants shown in Table  1 ). The initial response space can be large, complex, and unorganized. For example, if we searched PubChem bioassay data for the 962 ToxCast compounds, we could identify 193 PubChem assays that have at least five actives among these compounds (accessed in December of 2013). By classifying the ToxCast compounds into four major categories, 52 we could compare the response profiles, consisting of the 193 PubChem assays, of different types of compounds (Figure 3 ). Compared to phthalate plasticizers, the pharmaceutical compounds and pesticides have been studied in most bioassays, and the active response ratios are relatively high.
It is understandable that most areas within the initial response map are either "no testing" or "inconclusive" (indicating that no conclusion could be made about the relevant compounds based on the testing data) because many bioassays have been applied only to a small portion of this large chemical set. Furthermore, the nature of HTS assays, many of which represent very specific interactions, results in a biased distribution of responses for the target chemicals (many more "inactive" than "active" data entries). Because not all of the bioassay data are relevant or useful for a particular type of toxicity, additional rational selection steps are needed to select useful information from the bulk of available big data.
■ THE USE OF BIOASSAY DATA TO PRIORITIZE ANIMAL TOXICANTS
There have been some studies that use current bioassay data to identify likely animal toxicants and/or prioritize them for future experimental animal testing. For example, the currently available ToxCast bioassays have been organized into a global scoring system, called Toxicological Priority Index (ToxPi), to identify potential toxicants by their responses in these assays. 44, 47, 49, 52, 53 ToxPi, which is a dimensionless index score, was calculated as a weighted combination of all data sources that represents a formalized, rational integration of information from different types of ToxCast bioassays results. 49 Furthermore, toxicity pathways could also be generated, linking relevant bioassays together by analyzing their biological targets. 54, 55 ToxCast phase I is the first time there has been a big data effort to generate and systemically use large scale bioassay data in chemical toxicity studies. In ToxCast phase II, similar efforts continued with the new 767 target chemicals, including 111 failed pharmaceutical drug molecules. 52 In the recent Tox21 program, the results obtained from ToxCast were used to select the most useful bioassays as the testing battery for a much larger database. 24, 56, 57 There are other research groups and agencies that use bioassays to study various in vivo toxicities, such as acute toxicity, 58−61 developmental toxicity, 62 and drug−drug interactions. 63 One example is the AcuteTox collaborative project initiated within the European Union. Its purpose is to develop alternative testing strategies that could replace animal testing for predicting human acute oral systemic toxicity. 61,64−68 Similar to ToxCast, AcuteTox generated large scale in vitro toxicity data from multiple bioassays. 65 All of these efforts contributed to the initial pool of big data for chemical toxicants.
The authors of this review have also utilized bioassay data to predict animal toxicity of organic compounds. In the first two of our studies, multiple qHTS data from NCGC bioassays were used as biological descriptors to develop predictive models for various animal toxicity end points. 69, 70 The models with hybrid (combination of chemical and biological) descriptors showed better predictivity than the traditional quantitative structure− activity relationship (QSAR) models using only chemical descriptors. In another study, the biological descriptors obtained from toxicogenomics data were used to model animal hepatotoxicity.
■ PROGRESS OF TOXICOLOGY IN THE BIG DATA ERA
The clear limitation of extrapolating results from in vitro assays to a whole organism is that each in vitro assay generally considers only one or several target sites rather than a comprehensive organism consisting of hundreds of potential targets. 72, 73 The practical solution is to form a large battery of diverse in vitro assays for a specific animal toxicity, such as the ToxCast strategy. 16, 22 In the toxicant profiling studies described above, each project was limited to the use of the data generated by its own HTS assays. This lack of data integration across multiple related toxicity databases is clearly a big and open issue. How to integrate large scale data sets from various sources is a key question that needs to be addressed in the current big data scenario. To realize this goal, novel data storage and management methods need to be developed. For example, it is clear that all HTS assays contain certain noise associated with experimental data. Experimental noise varies from assay to assay, but it is rarely less than 15% as is seen, for example, for the Ames mutagenicity test. 74 Even in the most recent HTS project, e.g., ToxCast, random errors still exists in the original dose−response data. 75 To solve this problem, quality control (QC) review is a necessary step to remove experimental errors. Furthermore, automatic data processing methods have been developed to identify hits (i.e., actives or toxic compounds) from quality-assured HTS data and to increase the data dissemination and reproducibility. 76 Future data management tools, which are specifically useful for big data analysis, should be able to normalize the HTS data from different sources into benchmark end points. Currently, some preliminary studies (e.g., CurveP 70 ) have been reported. In 2007, the NRC envisioned a new paradigm in which biologically important perturbations in key toxicity pathways would be evaluated with new approaches in modern toxicology studies. 5 In this book, the NRC defined the toxicity pathway as a cellular response pathway that would result in an adverse health effect when sufficiently perturbed. This was the first time the concept of toxicity pathways, and emphasis on the use of pathways to explain the complex toxicity mechanisms, was introduced. In the above section, some preliminary studies of toxicity pathway studies (e.g., ToxCast project) were introduced. 16 Driven by the urgent requirements of the mode of action (MOA) analysis in toxicity studies, the Organization for Economic Development and Cooperation (OECD) has funded the recent development of adverse outcome pathway (AOP) development, which greatly advanced the area of ecotoxicology. 77 The AOP models have been successfully applied to skin sensitization evaluations. 78 To incorporate more toxicity data, especially the daily updated big data pool as shown in Table 1 , into toxicity models (e.g., toxicity pathways), novel data mining tools need to be developed to extract useful data from different resources. Wild and his co-workers developed a framework called Chem2-Bio2RDF to link several data resources, such as DrugBank, PubChem, ChEMBL, and others. 79 This framework, including other similar data mining tools developed in the same group, was used to create complex systems biology models (e.g., for drug adverse effects). 79−81 Recently, Fourches et al. reported a newly developed software, named HTS Navigator, to extract, visualize, and analyze HTS data from various resources. 82 Among emerging approaches specific to big data analysis, two key developments are semantic text-mining, 83 which helps bridge the language barrier across data sources with different ontologies, and large scale network analysis, to identify groups of related entities for further processing. 84 In the current big data scenario, the most critical issue is to identify useful in vitro data. In principle, this could be done by a human expert using the knowledge of the design and quality of each particular bioassay (e.g., confidence score assigned during manual curation to each assay in ChEMBL). We, however, believe that data-driven approaches would provide more efficient ways to accomplish this. One possible strategy is to select assays based on their in vitro−in vivo relationships. Because there are multiple mechanisms behind each toxicity phenotype, each bioassay is likely to show only partial correlation with in vivo effect. For example, if a bioassay represents a receptor that belongs to a toxicity pathway relevant to the target animal toxicity, then this bioassay should provide useful information, such as receptor/pathway perturbation. However, if compounds show inactive results in a particular bioassay, then they can still be toxic because they may bind to other target sites (Figure 4) . Indeed, our previous study showed that the bioassay results have a low false-positive rate to predict the relevant animal toxicity. 85 The false-negative rate, on the contrary, is high. On the basis of this study, we recently developed an automatic bioassay system to evaluate and extract the relevant bioassay data based on the in vitro−in vivo relationship. In our most recent publications, we developed an approach that could identify the most relevant bioassays as alternatives for animal toxicity models. 86 In this study, we initially extracted over 12 000 bioassays and around half million data points for 2000 compounds with animal toxicity results. By using the in vitro−in vivo relationship, which was described in Figure 4 , as the criteria, we developed a novel approach to select the most relevant bioassays to acute rat toxicity. The top 47 bioassays could be used to prioritize animal toxicants for future experimental testing in animals. Interestingly, the top potential animal toxicants, which have similar active responses in these bioassays, have dissimilar chemical structures.
■ CONCLUSIONS
Current innovative technologies enable rapid synthesis and high-throughput screening of large libraries of compounds. Daily updated toxicity bioassay data have transformed current toxicology studies into big data analysis. Fueled by the recent input from the U.S. and European governments, there are many ongoing data-generation and data-sharing programs, accompanied by the development of data curation and automated data management (e.g., "EMBL-EBI" KNIME workflow nodes for ChEMBL, "rpubchem" R package to PubChem) approaches that could be used to sample HTS data in meaningful formats to facilitate chemical toxicity studies. New scoring and modeling methods are also under way to take advantage of the massive amount of bioassay data. Although the use of bioassay data in most current toxicological research projects is still limited to a small portion of well-sampled HTS data, several novel approaches have been reported to be able to access and integrate multiple bioassay data resources to profile toxicants. Under the current big data scenario, it is expected that modern toxicology research will be able to better estimate the systemic effects of compounds on whole organisms and to translate this into better informed regulation of toxicants for animals and humans. 
